biostudies-literaturePetty WJFDA HHSNCI NIH HHS404https://www.ebi.ac.uk/biostudies/studies/S-EPMC3495013biostudies-literatureUnknown12In a phase I study of angiotensin-(1-7) [Ang-(1-7)], clinical benefit was associated with reduction in plasma placental growth factor (PlGF) concentrations. The current study examines Ang-(1-7) induced changes in biomarkers according to cancer type and investigates mechanisms of action engaged in vitro.Plasma biomarkers were measured prior to Ang-(1-7) administration as well as 1, 2, 3, 4, and 6?hours after treatment. Tests for interaction were performed to determine the impact of cancer type on angiogenic hormone levels. If a positive interaction was detected, treatment-induced biomarker changes for individual cancer types were assessed. To investigate mechanisms of action, in vitro growth assays were performed using a murine endothelioma cell line (EOMA). PCR arrays were performed to identify and statistically validate genes that were altered by Ang-(1-7) treatment in these cells.Tests for interaction controlled for dose cohort and clinical response indicated a significant impact of cancer type on post-treatment VEGF and PlGF levels. Following treatment, PlGF levels decreased over time in patients with sarcoma (P?=?.007). Treatment of EOMA cells with increasing doses of Ang-(1-7) led to significant growth suppression at doses as low as 100 nM. PCR arrays identified 18 genes that appeared to have altered expression after Ang-(1-7) treatment. Replicate analyses confirmed significant changes in 8 genes including reduction in PlGF (P?=?.04) and hypoxia inducible factor 1? (HIF-1?) expression (P?<?.001).Ang-(1-7) has clinical and pre-clinical activity for vascular sarcomas that is linked to reduced HIF-1? and PlGF expression.BMC cancerReverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1? in vascular sarcomas.PMC3495013P30-CA012197R01-FD003936Petty WJAklilu MVarela VALovato JMiller AASavage PDfalseReverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1? in vascular sarcomas.In a phase I study of angiotensin-(1-7) [Ang-(1-7)], clinical benefit was associated with reduction in plasma placental growth factor (PlGF) concentrations. The current study examines Ang-(1-7) induced changes in biomarkers according to cancer type and investigates mechanisms of action engaged in vitro.Plasma biomarkers were measured prior to Ang-(1-7) administration as well as 1, 2, 3, 4, and 6?hours after treatment. Tests for interaction were performed to determine the impact of cancer type on angiogenic hormone levels. If a positive interaction was detected, treatment-induced biomarker changes for individual cancer types were assessed. To investigate mechanisms of action, in vitro growth assays were performed using a murine endothelioma cell line (EOMA). PCR arrays were performed to identify and statistically validate genes that were altered by Ang-(1-7) treatment in these cells.Tests for interaction controlled for dose cohort and clinical response indicated a significant impact of cancer type on post-treatment VEGF and PlGF levels. Following treatment, PlGF levels decreased over time in patients with sarcoma (P?=?.007). Treatment of EOMA cells with increasing doses of Ang-(1-7) led to significant growth suppression at doses as low as 100 nM. PCR arrays identified 18 genes that appeared to have altered expression after Ang-(1-7) treatment. Replicate analyses confirmed significant changes in 8 genes including reduction in PlGF (P?=?.04) and hypoxia inducible factor 1? (HIF-1?) expression (P?<?.001).Ang-(1-7) has clinical and pre-clinical activity for vascular sarcomas that is linked to reduced HIF-1? and PlGF expression.2012-01-01T00:00:00Z2012 Sep2021-02-20T04:37:04Z2019-03-27T01:00:18ZS-EPMC34950132296350010.1186/1471-2407-12-404